Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
More News related to CELG
- Celgene Corporation to Present at the 27th Annual JPMorgan Healthcare Conference
- XplosiveStocks.com:DLTR, INFY, ENDP, CTSH, CELG, PLCM Hot Stocks on the Move
- BridgewaterEquity.com Free Fundamental Sector & Market Research on SOHU, JBLU, PLCM and CELG
- Ameriprise Financial Names Celgene (CELG) a Top Pick for 2009
- Baird Downgrades Celgene (CELG) to Neutral
More News related to FDA
- Deutsche Bank Downgrades and Lowers Estimates On Global Metals and Mining Companies (RIO, AAUK)
- Soleil Securities Maintains a Buy on Airgas (ARG), Lowers Estimates and Price Target
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
A drug designated as a Fast Track product is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to provide a therapy where none exists or provide a therapy which may offer a significant improvement in safety and/or effectiveness over existing therapy.
Related Categories
FDAStocks Mentioned
-0.84Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
